IKT
Inhibikase Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
inhibikase therapeutics, inc., a clinical stage pharmaceutical company, develops therapeutics for parkinson's disease, and related disorders that arise inside and outside of the brain. the company's product candidates include ikt-148009, a c-abl protein kinase inhibitor for use in the treatment of parkinson's disease, dysphagia, and neurogenic constipation; and ikt-001pro, a prodrug of the anti-cancer agent imatinib that is in preclinical development to minimize gastrointestinal side effects. it offers products comprise ikt-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and ikt-148x series of portfolio compounds for use in the treatment of dementia with lewy body and multiple system atrophy. the company was founded in 2008 and is headquartered in atlanta, georgia.
Market Cap: 14.9 Million
Primary Exchange: NASDAQ
Website: http://www.inhibikase.com/
Shares Outstanding: 6.17 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.14353713668615004
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 1041 trading days
From: 2020-12-24 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|